ContributorsPublishersAdvertisers

#Fluvoxamine

Columbus Dispatch

Antidepressant drug fluvoxamine may help reduce COVID hospitalization, study suggests

A cheap antidepressant may help reduce COVID-19 hospitalizations and provide a more affordable way to stop severe disease, a study from Brazil found. Fluvoxamine, typically used to treat depression and obsessive-compulsive disorder, can have anti-inflammatory effects and would cost only $4 for a course of COVID-19 treatment, compared to $2,000 for IV antibody treatments and $700 for Merck's antiviral COVID pill.
HEALTH
Picture for Antidepressant drug fluvoxamine may help reduce COVID hospitalization, study suggests
SHAPE

This Antidepressant Might Help Reduce COVID-19 Hospitalizations

When it comes to tackling the COVID-19 pandemic, health experts have a collection of ongoing tasks, including the prevention of infections by way of widespread vaccinations and curtailing serious illness (such as hospitalizations) in those who do contract the virus. As Americans await more information regarding the vaccine boosters, notably...
PUBLIC HEALTH
Picture for This Antidepressant Might Help Reduce COVID-19 Hospitalizations
TRENDING TOPICS

Cheap Antidepressant Might Help Keep COVID Patients Out of Hospital

THURSDAY, Oct. 28, 2021 (HealthDay News) -- A cheap and widely available antidepressant drug called fluvoxamine may reduce COVID-19 patients' risk of serious illness requiring hospitalization, according to a new study. The trial included almost 1,500 unvaccinated outpatients in Brazil. All of the patients tested positive for infection with SARS-CoV-2...
PUBLIC HEALTH
Vox

How a cheap antidepressant emerged as a promising Covid-19 treatment

Since Covid-19 patients started showing up at clinics and hospitals a year and a half ago, doctors and researchers have been hard at work trying to figure out how to treat them. Most drugs and treatments haven’t panned out, producing either no results or small ones in large-scale clinical trials. Many of the few that work are expensive and difficult to administer.
PUBLIC HEALTH
EurekAlert

Depressed COVID patients respond better than expected to antidepressants

The COVID pandemic has led to a significant increase in mental health problems. Now, in some good news, a pilot study has shown that depressed patients who have suffered from COVID respond better to standard antidepressants than do people who have not had COVID. Around 40% of COVID sufferers report...
MENTAL HEALTH
optometrytimes.com

Fluvoxamine can prevent COVID-19 from developing life-threatening conditions

The inexpensive drug works by suppressing the body’s natural defenses. An inexpensive, oral, generic antidepressant, fluvoxamine, could prevent COVID-19 from becoming a life-threatening condition, according to study results led by Edward Mills, PhD, FRCP, and researchers at McMaster University, Toronto, Canada. The TOGETHER Randomized Platform Clinical Trial evaluated the drug...
PUBLIC HEALTH
WSMV

Clinical Trial Seeks to Repurpose FDA Approved Drugs as COVID Treatment

NASHVILLE, TN (WSMV) — Brent Hendrickson still has fatigue and intermittent headaches after recovering from COVID-19. “I was not vaccinated. I made a personal choice to wait and see a little more research on it. Then I got it and we move forward from there,” said Hendrickson. After testing positive,...
NASHVILLE, TN
MedPage Today

Tech Entrepreneur Crusades for SSRI as COVID Therapy

Since the early days of the pandemic, researchers have been trying to use old drugs for new tricks, raising hopes and spurring controversy. Some of these, like hydroxychloroquine, turned out to be flops, while others are still debated. Recently, another old drug called fluvoxamine has come onto the scene. MedPage Today explores how the old antidepressant has made its way to the COVID spotlight.
PUBLIC HEALTH
McKnight's

Post-COVID depression responds better than expected to SSRI drugs, study finds

More than 90% of COVID-19 patients respond significantly more than would be expected to common depression medications, the results of a new pilot study suggest. In fact, these patients responded better to selective serotonin reuptake inhibitors (SSRIs)— a widely-used class of antidepressants — than is typical for patients who have not had COVID-19, investigator Mario Mazza, M.D., San Raffaele University in Italy, said.
MENTAL HEALTH

What Is Fluvoxamine? OCD Drug Could Be Used to Treat COVID

An anti-depressant medication used to treat obsessive-compulsive disorder (OCD) may also be effective at treating some COVID cases, scientists say. The drug fluvoxamine, commonly sold under the brand name Luvox, has emerged as a candidate for early treatment of the disease, with studies suggesting it could prevent some people's symptoms progressing to the point of needing hospitalization.
SCIENCE
YOU MAY ALSO LIKE